Role of stromal cell-derived factor 1α pathway in bone metastatic prostate cancer

Nisha Gupta; Dan G Duda

doi:10.7555/JBR.30.20150114

Role of stromal cell-derived factor 1α pathway in bone metastatic prostate cancer

J Biomed Res. 2016 May;30(3):181-5. doi: 10.7555/JBR.30.20150114. Epub 2015 Nov 2.

Authors

Nisha Gupta¹, Dan G Duda²

Affiliations

¹ Steele Laboratories for Tumor Biology, Department of Radiation Oncology, Massachusetts General Hospital Research Institute, Harvard Medical School, 100 Blossom Street, Boston, MA 02114, USA.
² Steele Laboratories for Tumor Biology, Department of Radiation Oncology, Massachusetts General Hospital Research Institute, Harvard Medical School, 100 Blossom Street, Boston, MA 02114, USA. gduda@partners.org.

Abstract

Metastatic prostate cancer is one of the leading causes of cancer-related death in men. The primary site of metastasis from prostate cancers is the bone. During the last decade, multiple studies have pointed to the role of the stromal cell-derived factor 1 alpha (SDF1α)/CXCR4 axis in the metastatic spread of the disease, but the mechanisms that underlie this effect are still incompletely understood. In this review, we summarize the current understanding of the role of the SDF1α/CXCR4 pathway in bone metastatic prostate cancer. We also discuss the therapeutic potential of disrupting the interaction between prostate tumor cells and bone environment with focus on the SDF1α pathway.

Keywords: CXCR4; SDF1α; bone metastasis; prostate cancer.

Publication types

Review

Abstract

Publication types

Grants and funding